Fairvalue-Calculator Fairvalue-Calculator
EN DE

Simcere Pharmaceutical Group (SMHGF) Fair Value & Analysis

Healthcare · US · Market cap $3.8B

Price$1.49
Fair Value$1.22
Upside-18.1%
Quality95/100
Evidence: High Range $0.8600 – $1.74

Fair value as of: Jun 24, 2026

Analysis

Simcere Pharmaceutical Group (SMHGF) currently trades at $1.49, while our model-based Fair Value estimate is $1.22 — implying the stock looks roughly 18.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials. The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulato…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Simcere Pharmaceutical Group (SMHGF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.22 versus a price of $1.49 — about −18% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SMHGF?
Our 21-model fair value for Simcere Pharmaceutical Group is $1.22 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.49.
What is the quality score of SMHGF?
Simcere Pharmaceutical Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.